Details for Patent: 8,933,097

Which drugs does patent 8,933,097 protect, and when does it expire?

Patent 8,933,097 protects CHILDREN'S ALLEGRA ALLERGY and CHILDREN'S ALLEGRA HIVES and is included in one NDA.

This patent has forty-three patent family members in thirty-eight countries.

Summary for Patent: 8,933,097

Patent landscape, scope, and claims:

Title:	Fexofenadine suspension formulation
Abstract:	The present invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I.
Inventor(s):	Chrzan; Kazimierz (New Hope, PA), Haribhakti; Rajiv (Churchville, PA), Mermey; Matthew (Leawood, KS), Porcello; Curtis J. (Ewing, NJ), Silvey; Gary Lee (Overland Park, KS), Tran; Vinh (Leawood, KS), Agrawala; Prafulla (Kendall Park, NJ)
Assignee:	Sanofi-Aventis U.S. LLC (Bridgewater, NJ)
Application Number:	12/138,468
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 8,933,097

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chattem Sanofi	CHILDREN'S ALLEGRA ALLERGY	fexofenadine hydrochloride	SUSPENSION;ORAL	201373-001	Jan 24, 2011		OTC	Yes	Yes	8,933,097		Y
Chattem Sanofi	CHILDREN'S ALLEGRA HIVES	fexofenadine hydrochloride	SUSPENSION;ORAL	201373-002	Jan 24, 2011		DISCN	Yes	No	8,933,097		Y

International Family Members for US Patent 8,933,097

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	058323
Austria	E431137
Australia	2006326551
Brazil	PI0619895
Canada	2633086